CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Dose of Tinzaparin or DalteparinWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D013923 Thromboembolism NIH 0.27

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001907 Thromboembolism HPO 0.24

There is one clinical trial.

Clinical Trials

1 Patient Characteristics, Outcome and Thromboembolic Events Among Adult Critically Ill COVID-19 Patients With Different Anticoagulant Regimes at One of the Biggest Emergency Hospitals in Northern Europe, Sweden

The aims of the study are to to associate anticoagulation (AC) regime with outcome in critically ill patients with Covid-19. This will be done by describe baseline characteristics and comorbidities before hospital admission, level of organ support and dose of AC treatment and associate this with 28 days survival, survival outside ICU, thromboembolic event and bleeding complications.

NCT04412304 Covid-19 Thromboembolic Events Bleeding Drug: Dose of Tinzaparin or Dalteparin
MeSH:Thromboembolism
HPO:Thromboembolism

Primary Outcomes

Description: 28-days ICU mortality from admission to the ICU. Discontinue of ICU-care to palliative care counts as death.

Measure: 28-days ICU mortality

Time: 28 days from ICU-admission

Secondary Outcomes

Description: Thromboembolic events are defined as pulmonary emboli (PE), deep venous thrombus (DVT), ischemic stroke and other peripheral arterial emboli. PE is defined as PE verified by computer tomography or by findings of acute strain of the right heart on echocardiography combined with a clinical interpretation of the patients deteriorating as a probable PE stated in the medical records. DVT is defined as DVT verified with ultrasound. Ischemic stroke is defined as ischemic stroke verified by computer tomography. Peripheral arterial emboli are defined as peripheral arterial emboli verified by computer tomography.

Measure: Incidence of thromboembolic events

Time: 28 days from ICU-admission

Description: The event of bleeding will be defined by WHO modified bleeding scale as 1-4.

Measure: Incidence of bleeding events

Time: 28 days from ICU-admission

Description: ICU-free days alive during 28 days from ICU-admission. Counts as 0 days if discharged to ward for palliative treatment.

Measure: ICU-free days alive from ICU-admission.

Time: 28 days from ICU-admission

Other Outcomes

Description: D-dimer every day it is measured during first 28 days from ICU-admission.

Measure: D-dimer levels in the three groups groups

Time: 28 days from ICU-admission

Related HPO nodes (Using clinical trials)

HP:0001907: Thromboembolism
Genes 27
HABP2 INHBA KCNN4 CYTB KIF20A MTRR CBS F2 FCGR2C SERPINC1 TNNT2 MTHFR KCNQ1 SLC4A1 PRDX1 TNNI3 MYPN ADA2 MMACHC PRKAR1A FLNC F13A1 PIEZO1 JAK2 PIGA EPOR HRG
Protein Mutations 3
G20210A G21210A R506Q
SNP 7
rs10276036 rs1128503 rs1202167 rs1202168 rs1202169 rs2235046 rs4148738